Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues
Reexamination Certificate
2006-12-07
2009-10-06
Ouspenski, Ilia (Department: 1644)
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
C514S012200
Reexamination Certificate
active
07598345
ABSTRACT:
The invention provides conjugates comprising an immune co-stimulatory polypeptide and an antigen or infectious agent. The conjugates are useful for generating or enhancing an immune response against the antigen or infectious agent. The invention also provides immune cells modified with a conjugate that are useful for generating or enhancing an immune response to an antigen or infectious agent. The invention also provides immunostimulatory moieties comprising an immune co-stimulatory polypeptide that are useful for stimulating an immune response. The invention also provides immunotherapy methods and methods of treating or preventing infections.
REFERENCES:
patent: 6232088 (2001-05-01), Franklin et al.
patent: 7238360 (2007-07-01), Shirwan
patent: 2003/0219419 (2003-11-01), Shirwan
patent: 2006/0052295 (2006-03-01), Terman
patent: 2007/0172504 (2007-07-01), Shirwan et al.
patent: 2007/0172947 (2007-07-01), Shirwan et al.
patent: WO 00/67788 (2000-11-01), None
patent: WO 02/02751 (2002-01-01), None
Asai, T. et al., “A human biotin acceptor domain allows site-specific conjugation o fan enzyme to an antibody-avidin fusion protein for targeted drug delivery”, Biomolecular Engineering, vol. 21, No. 6, pp. 145-155 (2005).
Huang, T-H, “Improved immunogenicity of a self-tumor antigen by covalent linkage to CD40 ligand”, Intl J. Cancer, vol. 108, pp. 696-703 (2004).
Huang, T-H, et al., “Enhanced antitumor immunity by fusion of CTLA-4 to a self tumor antigen”, Blood, vol. 96, No. 12, pp. 3663-3670 (2000).
Rohrbach, F., et al., “Targeted delivery of the ErbB2/HER2 tumor antigen to professional APCs results in effective antitumor immunity”, J. Immuno., vol. 174, No. 9, pp. 5481-5489 (2005).
Askenasy, Nadir et al., “Display of Fas Ligand Protein on Cardiac Vasculature as a Novel Means of Regulating Allograft Rejection”,Circulation, vol. 107, No. 11, pp. 1525-1531 (2003).
Briones, Javier et al., “Antitumor Immunity After Vaccination With B Lymphoma Cells Overexpressing a Triad of Costimulatory Molecules”,Journal of the National Cancer Institute, vol. 95, No. 7, pp. 548-555 (2003).
Kilinc, Mehmet O. et al., “Generation of a multimeric form of CD40L with potent immunostimulatory activity using streptavidin as a chaperon”,Experimental and Molecular Pathology, vol. 80, No. 3, pp. 252-261 (2006).
Hodge, James W. et al., “A Triad of Costimulatory Molecules Synergize to Amplify T-Cell Activation”,Cancer Research, vol. 59, pp. 5800-5807 (1999).
Singh, Narendra P. et al., “A Novel Approach to Cancer Immunotherapy: Tumor Cells Decorated with CD80 Generate Effective Antitumor Immunity”,Cancer Research, vol. 63, No. 14, pp. 4067-4073 (2003).
Singh, Narendra P. et al., “ProtEx™: A Novel Technology to Display Exogenous Proteins on the Cell Surface for Immunomodulation”,Ann. N.Y. Acad. Sci., vol. 1056, pp. 344-358 (2005).
Singh, Narendra P. et al., “Primary Tumor Cells Resected from Cancer Patients and Decorated with a Novel Form of CD80 Protein Serve as Effective Antigen-Presenting Cells for the Induction of Autologous T Cell Immune Responses Ex Vivo”,Human Gene Therapy, vol. 17, No. 3, pp. 334-346 (2006).
Yolcu, Esma S. et al., “Cell Membrane Modification for Rapid Display of Proteins as a novel Means of Immunomodulation: FasL-Decorated Cells Prevent Islet Graft Rejection”,Immunity, 17:795-808 (2002).
Moro, Monica et al., “Induction of Therapeutic T-Cell Immunity by tumor Targeting with Soluble Recombinant B7-Immunoglobulin Costimulatory Molecules”,Cancer Research, vol. 59, No. 11, pp. 2650-2656 (1999).
Symington, Frank W. et al., “Expression and Function of B7 on Human Epidermal Langerhans Cells”,Journal of Immunology, vol. 150, No. 4, pp. 1286-1295 (1993).
Kudo-Saito, Chie et al., “Intratumoral Vaccination and Diversified Subcutaneous/Intratumoral Vaccination with Recombinant Poxviruses Costimulatory Molecules”,Clincal Cancer Research, vol. 10, No. 3, pp. 1090-1099 (2004).
De Jong, Marg O. et al., “Biotinylation of interleukin-s (IL-2) for flow cytometric analysis of IL-2 receptor expression”,J. Immunol. Methods, 184:101-112 (1995).
Jordan, Robert A. et al., “Production of Genetically Engineered Biotinylated Interleukin-s and Its Applications in a Rapid Nonradioactive Assay for T-Cell Activation”,Clin.Diag. Lab. Immunol., vol. 10, No. 3, pp. 339-344 (2003).
Lynch,Immunological Reviews, 2008, 222:277-286.
Boon et al.,Annu. Rev. Immunol., 2006, 24:175-208.
Nielson et al.,Cancer Chemother. Pharmacol., 2000, 46 (Suppl.): S62-S66.
Lee et al.,J. Immunol., 1999, 163:6292-6300.
Blazer et al.,J. Immunol., 1996, 157:3250-3259.
Melero et al.,Eur. J. Immnol., 1998, 28:1116-1121.
International Search Report issued in application No. PCT/US2006/046662 (corresponding to US 2007/0172947), mailed Nov. 13, 2007.
Office Action dated Dec. 4, 2007, issued by the Examiner in U.S. Appl. No. 11/635,087 (US 2007/0172947).
Office Action dated Apr. 30, 2008, issued by the Examiner in U.S. Appl. No. 11/635,087 (US 2007/0172947).
Office Action dated Jan. 16, 2009, issued by the Examiner in U.S. Appl. No. 11/635,087 (US 2007/0172947).
Office Action dated Jan. 9, 2009, issued by the Examiner in U.S. Appl. No. 11/635,075 (US 2007/0172504).
Office Action dated Apr. 17, 2008, issued by the Examiner in U.S. Appl. No. 11/635,075 (US 2007/0172504).
Office Action dated Dec. 4, 2007, issued by the Examiner in U.S. Appl. No. 11/635,075 (US 2007/0172504).
International Search Report issued in application No. PCT/US2006/046663 (corresponding to US 2007/0172504), mailed Sep. 21, 2007.
Elpek Kutlu G.
Shirwan Haval
Yolcu Esma S.
Foley & Lardner LLP
Ouspenski Ilia
University of Louisville Research Foundation Inc.
LandOfFree
Immunostimulatory compositions and methods does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Immunostimulatory compositions and methods, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Immunostimulatory compositions and methods will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4136958